Targeted risk assessment for famoxadone

In accordance with Article 43 of Regulation (EC) No 396/2005, the European Commission requested EFSA to assess whether existing Codex Maximum Residue Limits (CXLs) for famoxadone are safe for consumers in light of the lowered toxicological reference values established following the non‐renewal of ap...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061275/
https://www.ncbi.nlm.nih.gov/pubmed/37009437
http://dx.doi.org/10.2903/j.efsa.2023.7932
_version_ 1785017260787630080
collection PubMed
description In accordance with Article 43 of Regulation (EC) No 396/2005, the European Commission requested EFSA to assess whether existing Codex Maximum Residue Limits (CXLs) for famoxadone are safe for consumers in light of the lowered toxicological reference values established following the non‐renewal of approval of the active substance famoxadone. Based on the targeted assessment EFSA identified a potential acute concern for the CXL on table grapes. For the other CXLs consumers intake concern was not identified.
format Online
Article
Text
id pubmed-10061275
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100612752023-03-31 Targeted risk assessment for famoxadone EFSA J Statement In accordance with Article 43 of Regulation (EC) No 396/2005, the European Commission requested EFSA to assess whether existing Codex Maximum Residue Limits (CXLs) for famoxadone are safe for consumers in light of the lowered toxicological reference values established following the non‐renewal of approval of the active substance famoxadone. Based on the targeted assessment EFSA identified a potential acute concern for the CXL on table grapes. For the other CXLs consumers intake concern was not identified. John Wiley and Sons Inc. 2023-03-30 /pmc/articles/PMC10061275/ /pubmed/37009437 http://dx.doi.org/10.2903/j.efsa.2023.7932 Text en © 2023 European Food Safety Authority. EFSA Journal published by Wiley‐VCH GmbH on behalf of European Food Safety Authority. https://creativecommons.org/licenses/by-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nd/4.0/ (https://creativecommons.org/licenses/by-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
spellingShingle Statement
Targeted risk assessment for famoxadone
title Targeted risk assessment for famoxadone
title_full Targeted risk assessment for famoxadone
title_fullStr Targeted risk assessment for famoxadone
title_full_unstemmed Targeted risk assessment for famoxadone
title_short Targeted risk assessment for famoxadone
title_sort targeted risk assessment for famoxadone
topic Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061275/
https://www.ncbi.nlm.nih.gov/pubmed/37009437
http://dx.doi.org/10.2903/j.efsa.2023.7932
work_keys_str_mv AT targetedriskassessmentforfamoxadone

Ejemplares similares